S

ST Pharm Co Ltd
KOSDAQ:237690

Watchlist Manager
ST Pharm Co Ltd
KOSDAQ:237690
Watchlist
Price: 83 200 KRW -2.92% Market Closed
Market Cap: 1.7T KRW
Have any thoughts about
ST Pharm Co Ltd?
Write Note

ST Pharm Co Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ST Pharm Co Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
S
ST Pharm Co Ltd
KOSDAQ:237690
Cash & Cash Equivalents
â‚©50.1B
CAGR 3-Years
6%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Samsung Biologics Co Ltd
KRX:207940
Cash & Cash Equivalents
â‚©973.5B
CAGR 3-Years
129%
CAGR 5-Years
147%
CAGR 10-Years
N/A
K
Knotus Co Ltd
KOSDAQ:278650
Cash & Cash Equivalents
â‚©68.8B
CAGR 3-Years
105%
CAGR 5-Years
83%
CAGR 10-Years
N/A
F
FutureChem Co Ltd
KOSDAQ:220100
Cash & Cash Equivalents
â‚©5.4B
CAGR 3-Years
20%
CAGR 5-Years
33%
CAGR 10-Years
N/A
L
LegoChem Biosciences Inc
KOSDAQ:141080
Cash & Cash Equivalents
â‚©15.5B
CAGR 3-Years
5%
CAGR 5-Years
14%
CAGR 10-Years
61%
C
Cellivery Therapeutics Inc
KOSDAQ:268600
Cash & Cash Equivalents
â‚©589.8m
CAGR 3-Years
-72%
CAGR 5-Years
-38%
CAGR 10-Years
N/A
No Stocks Found

ST Pharm Co Ltd
Glance View

Market Cap
1.6T KRW
Industry
Life Sciences Tools & Services

ST Pharm Co., Ltd. develops and manufactures pharmaceutical products. The company is headquartered in Siheung, Gyeonggi-Do. The company went IPO on 2016-06-23. is a Korea-based company principally engaged in manufacture of pharmaceutical products. The firm's products mainly consist of generic active pharmaceutical ingredients (APIs), such as tipepidine hibenzate, doxifluridine, clopidogrel bisulfate, voriconazole and new medicine APIs, such as small molecule APIs. The firm distributes its products within domestic market and to overseas markets.

Intrinsic Value
97 768.06 KRW
Undervaluation 15%
Intrinsic Value
Price
S

See Also

What is ST Pharm Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
50.1B KRW

Based on the financial report for Sep 30, 2024, ST Pharm Co Ltd's Cash & Cash Equivalents amounts to 50.1B KRW.

What is ST Pharm Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
33%

Over the last year, the Cash & Cash Equivalents growth was 133%. The average annual Cash & Cash Equivalents growth rates for ST Pharm Co Ltd have been 6% over the past three years , 33% over the past five years .

Back to Top